Back to Search Start Over

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Authors :
Krastins B
Prakash A
Sarracino DA
Nedelkov D
Niederkofler EE
Kiernan UA
Nelson R
Vogelsang MS
Vadali G
Garces A
Sutton JN
Peterman S
Byram G
Darbouret B
Pérusse JR
Seidah NG
Coulombe B
Gobom J
Portelius E
Pannee J
Blennow K
Kulasingam V
Couchman L
Moniz C
Lopez MF
Source :
Clinical biochemistry [Clin Biochem] 2013 Apr; Vol. 46 (6), pp. 399-410. Date of Electronic Publication: 2013 Jan 08.
Publication Year :
2013

Abstract

Objectives: The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum.<br />Design and Methods: The described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and accurate quantification of targeted peptides, including clinically relevant sequence or truncated variants.<br />Results: In this report, we demonstrate the rapid development of MSIA-SRM assays for sixteen different target proteins spanning seven different clinically important areas (including neurological, Alzheimer's, cardiovascular, endocrine function, cancer and other diseases) and ranging in concentration from pg/mL to mg/mL. The reported MSIA-SRM assays demonstrated high sensitivity (within published clinical ranges), precision, robustness and high-throughput as well as specific detection of clinically relevant isoforms for many of the target proteins. Most of the assays were tested with bona-fide clinical samples. In addition, positive correlations, (R2 0.67-0.87, depending on the target peptide), were demonstrated for MSIA-SRM assay data with clinical analyzer measurements of parathyroid hormone (PTH) and insulin growth factor 1 (IGF1) in clinical sample cohorts.<br />Conclusions: We have presented a practical and scalable method for rapid development and deployment of MS-based SRM assays for clinically relevant proteins and measured levels of the target analytes in bona fide clinical samples. The method permits the specific quantification of individual protein isoforms and addresses the difficult problem of protein heterogeneity in clinical proteomics applications.<br /> (Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1873-2933
Volume :
46
Issue :
6
Database :
MEDLINE
Journal :
Clinical biochemistry
Publication Type :
Academic Journal
Accession number :
23313081
Full Text :
https://doi.org/10.1016/j.clinbiochem.2012.12.019